

University of Pennsylvania Pharmacogenomic Program Epic interruptive BPAs

LOCATOR ID	LOCATOR NAME	DISP COMMENT	CRITERIA	CRITERIA RECORD	LOGIC
1280000100	BASE PGX AMB CLOPIDOGREL/CYP2C19 INTERMEDIATE METABOLIZER	Pharmacogenetic Warning: Based on the CYP2C19 genetic testing result, this patient is predicted to have reduced activation of clopidogrel, resulting in decreased efficacy, such as increased risk of cardiovascular events. If clopidogrel is being prescribed for ACS, PCI, or for neurovascular indications, use an alternative P2Y12 inhibitor. For more information please contact a clinical pharmacist. See CPIC guidelines or PharmGKB link below for more information.	1395	CL PATIENT ON CLOPIDOGREL	1 AND 2
			128000014	CL PGX CYP2C19 INTERMEDIATE METABOLIZER GENOMIC INDICATOR	
1280000101	BASE PGX AMB CLOPIDOGREL/CYP2C19 POOR METABOLIZER	Pharmacogenetic Warning: Based on the CYP2C19 genetic testing result, this patient is predicted to have greatly reduced activation of clopidogrel, resulting in greatly decreased efficacy, such as increased risk of cardiovascular events. Use an alternative P2Y12 inhibitor. For more information, please contact a clinical pharmacist. See CPIC guidelines or PharmGKB link below for more information.	1395	CL PATIENT ON CLOPIDOGREL	1 AND (2 OR 3 OR 4)
			128000010	CL PGX CYP2C19 POOR METABOLIZER GENOMIC INDICATOR	
			1606	CL CYP2C19 RESULT FOR REDUCED CLOPIDOGREL EFFICACY	
			2493	CL CYP2C19 RESULT FOR POOR CLOPIDOGREL EFFICACY	
1280000113	BASE PGX INP CLOPIDOGREL/CYP2C19 INTERMEDIATE METABOLIZER	Pharmacogenetic Warning: Based on the CYP2C19 genetic testing result, this patient is predicted to have reduced activation of clopidogrel, resulting in decreased efficacy, such as increased risk of cardiovascular events. If clopidogrel is being prescribed for ACS, PCI, or for neurovascular indications, use an alternative P2Y12 inhibitor. For more information please contact a clinical pharmacist. See CPIC guidelines or PharmGKB link below for more information.	1395	CL PATIENT ON CLOPIDOGREL	1 AND 2
			128000014	CL PGX CYP2C19 INTERMEDIATE METABOLIZER GENOMIC INDICATOR	
4807	BASE PGX INP CLOPIDOGREL/CYP2C19 POOR METABOLIZER	Pharmacogenetic Warning: Based on the CYP2C19 genetic testing result, this patient is predicted to have greatly reduced activation of clopidogrel, resulting in greatly decreased efficacy, such as increased risk of cardiovascular events. Use an alternative P2Y12 inhibitor. For more information, please contact a clinical pharmacist. See CPIC guidelines or PharmGKB link below for more information.	1395	CL PATIENT ON CLOPIDOGREL	1 AND (2 OR 3 OR 4)
			128000010	CL PGX CYP2C19 POOR METABOLIZER GENOMIC INDICATOR	
			1606	CL CYP2C19 RESULT FOR REDUCED CLOPIDOGREL EFFICACY	
			2493	CL CYP2C19 RESULT FOR POOR CLOPIDOGREL EFFICACY	